ES2911690T3 - Regulación del metabolismo de la glucosa mediante anticuerpos anti-CGRP - Google Patents

Regulación del metabolismo de la glucosa mediante anticuerpos anti-CGRP Download PDF

Info

Publication number
ES2911690T3
ES2911690T3 ES14820173T ES14820173T ES2911690T3 ES 2911690 T3 ES2911690 T3 ES 2911690T3 ES 14820173 T ES14820173 T ES 14820173T ES 14820173 T ES14820173 T ES 14820173T ES 2911690 T3 ES2911690 T3 ES 2911690T3
Authority
ES
Spain
Prior art keywords
seq
cgrp
antibody
sequence
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14820173T
Other languages
English (en)
Spanish (es)
Inventor
John A Latham
Jeffrey T L Smith
Brian Baker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Application granted granted Critical
Publication of ES2911690T3 publication Critical patent/ES2911690T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Developing Agents For Electrophotography (AREA)
ES14820173T 2013-07-03 2014-07-03 Regulación del metabolismo de la glucosa mediante anticuerpos anti-CGRP Active ES2911690T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361842745P 2013-07-03 2013-07-03
US201461982611P 2014-04-22 2014-04-22
PCT/US2014/045389 WO2015003122A2 (en) 2013-07-03 2014-07-03 Regulation of glucose metabolism using anti-cgrp antibodies

Publications (1)

Publication Number Publication Date
ES2911690T3 true ES2911690T3 (es) 2022-05-20

Family

ID=52144290

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14820173T Active ES2911690T3 (es) 2013-07-03 2014-07-03 Regulación del metabolismo de la glucosa mediante anticuerpos anti-CGRP

Country Status (14)

Country Link
US (1) US20150017166A1 (cg-RX-API-DMAC10.html)
EP (1) EP3016684B1 (cg-RX-API-DMAC10.html)
JP (4) JP6502337B2 (cg-RX-API-DMAC10.html)
KR (1) KR102476907B1 (cg-RX-API-DMAC10.html)
CN (1) CN105492026B (cg-RX-API-DMAC10.html)
AU (2) AU2014285052B2 (cg-RX-API-DMAC10.html)
CA (1) CA2916980C (cg-RX-API-DMAC10.html)
ES (1) ES2911690T3 (cg-RX-API-DMAC10.html)
IL (1) IL243355B2 (cg-RX-API-DMAC10.html)
MX (1) MX374612B (cg-RX-API-DMAC10.html)
NZ (1) NZ754427A (cg-RX-API-DMAC10.html)
SG (2) SG11201510618YA (cg-RX-API-DMAC10.html)
TW (2) TWI712419B (cg-RX-API-DMAC10.html)
WO (1) WO2015003122A2 (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150017166A1 (en) * 2013-07-03 2015-01-15 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
MX378344B (es) 2014-03-21 2025-03-10 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos.
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
SMT202600087T1 (it) 2016-09-23 2026-03-09 Teva Pharmaceuticals Int Gmbh Trattamento dell’emicrania refrattaria
KR20210124867A (ko) 2020-04-06 2021-10-15 하. 룬드벡 아크티에셀스카브 항-cgrp 항체를 사용하는 편두통 관련 성가심 증상 (mbs) 의 치료
EP4196611A1 (en) * 2020-08-15 2023-06-21 Regeneron Pharmaceuticals, Inc. Treatment of obesity in subjects having variant nucleic acid molecules encoding calcitonin receptor (calcr)
CN117813325A (zh) 2021-08-27 2024-04-02 H.隆德贝克有限公司 使用抗cgrp抗体治疗丛集性头痛
WO2025262247A1 (en) 2024-06-21 2025-12-26 H. Lundbeck A/S Treatment of headache disorders and/or psychiatric symptoms using anti-cgrp antibodies, and compositions and methods related thereto

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
GB8720115D0 (en) 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
DE68924372T2 (de) * 1988-01-11 1996-05-09 Amylin Pharmaceuticals Inc Behandlung von diabetes mellitus typ 2.
US5266561A (en) * 1988-01-11 1993-11-30 Amylin Pharmaceuticals, Inc. Treatment of type 2 diabetes mellitus
US5364841A (en) * 1988-01-11 1994-11-15 Amylin Pharmaceuticals, Inc. Treatment of obesity and essential hypertension and related disorders
US5175145A (en) 1988-08-26 1992-12-29 Amylin Pharmaceuticals, Inc. Treatment of diabetes mellitus with amylin agonists
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
DE68923790T2 (de) * 1989-01-03 1996-05-15 Motorola Inc Verfahren zum herstellen von löthöckern hoher dichte und ein substratsockel für löthöcker hoher dichte.
US5766883A (en) 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
IE71195B1 (en) * 1989-07-10 1997-02-12 Amylin Corp Use of an amylin antagonist for the manufacture of a medicament for the treatment of obesity and essential hypertension and related disorders
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
AU6445894A (en) 1993-03-19 1994-10-11 Duke University Method of treatment of tumors with an antibody binding to tenascin
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
AU3272695A (en) 1994-08-12 1996-03-07 Immunomedics Inc. Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
US6653104B2 (en) 1996-10-17 2003-11-25 Immunomedics, Inc. Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
EP1461068A4 (en) * 2001-11-26 2006-03-29 Protemix Corp Ltd METHOD AND COMPOSITIONS FOR NORMALIZING LIPID MIRRORS IN MIRACLE TISSUE
DK1678314T3 (da) 2003-10-22 2012-12-03 Keck Graduate Inst Fremgangsmåde til syntetisering af heteromultimere polypeptider i gær ved anvendelse af en haploid parringsstrategi
SI3045182T1 (en) * 2005-11-14 2018-08-31 Teva Pharmaceuticals International Gmbh An antibody to a peptide-associated peptide antagonist to calcitonin for treating a headache in aggregates
EP2021463B1 (en) 2006-05-19 2016-11-23 Alder Biopharmaceuticals, Inc. Culture method for obtaining a clonal population of antigen-specific b cells
NZ601583A (en) 2007-05-21 2013-08-30 Bristol Myers Squibb Co Novel rabbit antibody humanization methods and humanized rabbit antibodies
DK2164514T3 (en) 2007-05-21 2017-02-27 Alderbio Holdings Llc Antibodies to IL-6 and its use
WO2008144753A2 (en) 2007-05-21 2008-11-27 Alder Biopharmaceuticals, Inc. Antibodies to tnf alpha and use thereof
PT3495392T (pt) * 2011-05-20 2021-09-22 H Lundbeck As Composições anti-cgrp e a sua utilização
EA033109B1 (ru) * 2011-05-20 2019-08-30 Олдербайо Холдингз Ллк Способы ингибирования, профилактики или лечения диареи и/или поддержания соответствующих уровней электролитов и жидкости в толстой кишке субъекта, подвергающегося связанному с диареей состоянию, с помощью антитела против cgrp или фрагмента антитела против cgrp
US20150017166A1 (en) * 2013-07-03 2015-01-15 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies

Also Published As

Publication number Publication date
SG10201906172XA (en) 2019-08-27
KR102476907B1 (ko) 2022-12-13
JP2018168186A (ja) 2018-11-01
EP3016684A2 (en) 2016-05-11
IL243355B2 (en) 2024-10-01
MX374612B (es) 2025-03-06
CN105492026B (zh) 2025-12-30
AU2019279945B2 (en) 2022-01-20
AU2014285052B2 (en) 2019-09-12
TW202106335A (zh) 2021-02-16
MX2016000220A (es) 2016-08-18
NZ715834A (en) 2021-11-26
AU2019279945A1 (en) 2020-01-16
JP6502337B2 (ja) 2019-04-17
EP3016684A4 (en) 2017-06-07
JP2020158525A (ja) 2020-10-01
CA2916980A1 (en) 2015-01-08
CN105492026A (zh) 2016-04-13
WO2015003122A3 (en) 2015-03-19
JP2016528198A (ja) 2016-09-15
EP3016684B1 (en) 2022-02-23
AU2014285052A1 (en) 2016-02-11
NZ754427A (en) 2021-12-24
TW201536316A (zh) 2015-10-01
SG11201510618YA (en) 2016-03-30
WO2015003122A2 (en) 2015-01-08
TWI753471B (zh) 2022-01-21
IL243355B1 (en) 2024-06-01
JP2019112455A (ja) 2019-07-11
CA2916980C (en) 2023-02-21
TWI712419B (zh) 2020-12-11
IL243355A0 (en) 2016-03-31
US20150017166A1 (en) 2015-01-15
KR20160029822A (ko) 2016-03-15

Similar Documents

Publication Publication Date Title
AU2019279945B2 (en) Regulation of glucose metabolism using anti-CGRP antibodies
US12122821B2 (en) Regulation of glucose metabolism using anti-CGRP antibodies
US11027018B2 (en) Use of anti-CGRP antibodies and antibody fragments to treat diarrhea in subjects with diseases or treatments that result in elevated CGRP levels
ES2993942T3 (en) Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
EP3434691A1 (en) Anti-ngf compositions and use thereof
RS61793B1 (sr) Anti-cgrp kompozicije i njihova upotreba
BR112020018044A2 (pt) tratamento de dor de cabeça por uso excessivo de medicação usando anticorpos anti-cgrp ou anti-cgrp-r
US10221236B2 (en) Anti-NGF antibodies that selectively inhibit the association of NGF with TRKA without affecting the association of NGF with P75
JP2026016471A (ja) 抗ｃｇｒｐ抗体を用いた頭痛の治療
NZ715834B2 (en) Regulation of glucose metabolism using anti-cgrp antibodies